Latest Healthcare Innovation News

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

InteliCare Holdings announces CEO Daniel Pilbrow’s resignation effective October 2025, with Non-Executive Director Tim Chapman stepping in as interim executive director during the leadership transition.

Syntara Limited has initiated dosing in its Phase 1c SATELLITE trial for a novel topical treatment targeting keloid scars, marking a significant step in addressing a $3.5 billion global market. The study, led by Professor Fiona Wood, will evaluate safety and early efficacy over three months.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.